SCHEMBL6356442

SCHEMBL6356442

O=C(CN1CCC(c2cnccn2)C1)c1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.54
EPHX2 P34913 1/20 0.54
NAMPT P43490 1/20 0.54
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TSHR P16473 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HTR2A P28223 5/20 0.46
HTR2C P28335 4/20 0.46
KCNH2 Q12809 2/20 0.46
DRD2 P14416 4/20 0.45
HTR2B P41595 2/20 0.45
SIGMAR1 Q99720 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6360058 0.89 CYP2C9 (0.52) CYP2C9EPHX2NAMPTALDH1A1HTR2A
SCHEMBL6351436 0.84 DRD4 (0.48) CYP2C9EPHX2NAMPTALDH1A1KDM4E
SCHEMBL6351432 0.84 DRD4 (0.48) CYP2C9EPHX2NAMPTALDH1A1KDM4E
SCHEMBL6351409 0.81 DRD4 (0.52) CYP2C9EPHX2NAMPTHTR2AHTR2C
SCHEMBL6351565 0.81 DRD4 (0.52) CYP2C9EPHX2NAMPTHTR2AHTR2C
SCHEMBL6351411 0.81 DRD4 (0.52) CYP2C9EPHX2NAMPTHTR2AHTR2C
SCHEMBL6351385 0.78 NAMPT (0.46) CYP2C9EPHX2NAMPTHTR2ADRD2
SCHEMBL6351170 0.78 NAMPT (0.46) CYP2C9EPHX2NAMPTHTR2ADRD2
SCHEMBL6351165 0.78 NAMPT (0.46) CYP2C9EPHX2NAMPTHTR2ADRD2
SCHEMBL6352358 0.75 DRD4 (0.58) CYP2C9EPHX2NAMPTDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction CYP19A1, SHBG, CYP17A1 CYP2C9 290/4885EPHX2 651/4885NAMPT 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.